ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: GlobeNewswire
SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, November 13, 2024, at 8:00 a.m. ET to discuss its third quarter 2024 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event here. In addition, ARS Pharma Management will be participating in multiple upcoming investor conferences: Guggenheim’s Inaugural Healthcare Innovation Conference: fireside chat on November 13, 2024, at 1:00 p.m. ET (10:00 a.m. PT)Stifel Healthcare Conference: presentation on November 18, 2024, at 2:25 p.m. ET (11:25 a.m. PT)Jefferies London Healthcare Conference: investor meetings on November 20-21, 2024 To access the live and archive
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United StatesGlobeNewswire
- ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm Accesswire
- The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations Accesswire
SPRY
Earnings
- 8/6/24 - Miss
SPRY
Sec Filings
- 11/12/24 - Form 8-K
- 10/17/24 - Form 4
- 10/17/24 - Form 4
- SPRY's page on the SEC website